- Home
- ANVS vs SACH Comparison
ANVS vs SACH Comparison
Compare ANVS & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | SACH |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 48.6M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANVS | SACH |
|---|---|---|
| Price | $2.50 | $1.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $13.50 | $2.00 |
| AVG Volume (30 Days) | ★ 306.4K | 119.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 18.35% |
| EPS Growth | ★ 62.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.80 |
| 52 Week High | $5.50 | $1.35 |
Technical Indicators
Market Signals| Indicator | ANVS | SACH |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 69.13 |
| Support Level | $2.27 | $1.04 |
| Resistance Level | $2.63 | $1.13 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 21.54 | 80.51 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.